US 12,467,063 B2
Recombinant AAV vectors useful for reducing immunity against transgene products
Guangping Gao, Worcester, MA (US); Phillip D. Zamore, Worcester, MA (US); and Shaoyong Li, Worcester, MA (US)
Assigned to University of Massachusetts, Westborough, MA (US)
Filed by University of Massachusetts, Westborough, MA (US)
Filed on Mar. 5, 2021, as Appl. No. 17/193,030.
Application 17/193,030 is a continuation of application No. 15/306,543, granted, now 10,975,391, previously published as PCT/US2015/027591, filed on Apr. 24, 2015.
Claims priority of provisional application 62/001,280, filed on May 21, 2014.
Claims priority of provisional application 61/984,460, filed on Apr. 25, 2014.
Prior Publication US 2021/0317475 A1, Oct. 14, 2021
This patent is subject to a terminal disclaimer.
Int. Cl. C12N 15/63 (2006.01); A61K 38/17 (2006.01); A61K 38/28 (2006.01); A61K 38/44 (2006.01); A61K 38/48 (2006.01); A61K 38/51 (2006.01); A61K 48/00 (2006.01); C07K 16/10 (2006.01); C07K 16/22 (2006.01); C07K 16/28 (2006.01); C07K 16/32 (2006.01); C12N 7/00 (2006.01); C12N 7/01 (2006.01); C12N 15/113 (2010.01); C12N 15/117 (2010.01); C12N 15/86 (2006.01); C12N 15/864 (2006.01)
CPC C12N 15/86 (2013.01) [A61K 38/1709 (2013.01); A61K 38/28 (2013.01); A61K 38/446 (2013.01); A61K 38/4846 (2013.01); A61K 38/51 (2013.01); A61K 48/0008 (2013.01); C07K 16/1003 (2023.08); C07K 16/22 (2013.01); C07K 16/2875 (2013.01); C07K 16/2887 (2013.01); C07K 16/32 (2013.01); C12N 7/00 (2013.01); C12N 15/113 (2013.01); C12N 15/117 (2013.01); C12N 2310/141 (2013.01); C12N 2310/17 (2013.01); C12N 2320/30 (2013.01); C12N 2330/51 (2013.01); C12N 2710/10322 (2013.01); C12N 2710/10332 (2013.01); C12N 2750/14143 (2013.01); C12N 2760/00042 (2013.01); C12N 2830/008 (2013.01); C12Y 115/01001 (2013.01); C12Y 304/21022 (2013.01); C12Y 401/01028 (2013.01)] 12 Claims
 
1. A method of delivering a transgene to a subject, the method comprising administering to the subject a recombinant Adeno-Associated Virus (rAAV) comprising the transgene, wherein the transgene encodes an RNA transcript that comprises two different immune-associated miRNA binding sites, wherein the two different immune-associated miRNA binding sites bind a miRNA pair selected from: (i) miR-142-3p and miR-155, (ii) miR-181a and miR-21, (iii) miR-16-1 and miR-150, (iv) miR-146 and miR-181la, (v) miR-31 and miR-181a, (vi) miR-146a and miR-16-1, (vii) miR-150 and miR-18 1a, (viii) miR-16-1 and miR-181a, and (ix) miR-142-3p and miR-223.